During a speech given today in Washington, DC, FDA Commissioner Scott Gottlieb, MD, announced the release of the long-awaited Biosimilar Action Plan.
During a speech given today in Washington, DC, FDA Commissioner Scott Gottlieb, MD, announced the release of the long-awaited Biosimilar Action Plan.
The plan, posted simultaneously on the FDA website, is meant to spur biosimilar competition in the US marketplace by addressing 4 key areas:
“While less than 2% of Americans use biologics, they represent 40% of total spending on prescription drugs,” said Gottlieb. “So, enabling a path to competition for biologics from biosimilars is a key to reducing costs and facilitating more innovation.”
Gottlieb explained that the current payment system and reimbursement models in the United States were designed in a single-source world, where there was typically only 1 biologic in a category and there was a lack of therapeutic variety or competition. However, that is not the case anymore, as many of the biologic categories are highly competitive with many products targeting the same disease.
“And so, we need to adopt a different approach to paying for these drugs. An ideal system would reimburse biologics in a competitively bid scheme, where we could take full advantage of the multi-source competition," he said.
Although potential savings from biosimilars have been estimated to be quite high (a RAND study estimated biosimilars could offer a savings of $54 billion from 2017 to 2026), “The real savings has been just a fraction of even the most conservative initial estimates," Gottlieb said. "You don’t have to look far to understand why. While the FDA has approved 11 biosimilars through 2018, only 3 are marketed in the US. Competition is, for the most part, anemic.”
Gottlieb cited litigation for delaying market access of biosimilar products as one of the reasons for the lack of competition, which can come with costs for patients and payers. To analyze the cost of such delays, the FDA recently conducted an analysis of biosimilar competition across all Organization for Economic Co-operation and Development (OECD) markets, the full results of which will be released soon, according to Gottlieb.
However, the initial findings of the study, which assumed that the savings achieved in the United States from biosimilars in terms of price discounts would be on par with what has been seen in other OECD nations, found that if Americans had the opportunity to purchase FDA-approved and marketed biosimilars, they could have saved more than $4.5 billion in 2017. Importantly, these estimated savings does not include savings from biosimilars approved in 2018.
In addition to litigation delaying market access for biosimilars, Gottlieb discussed how rebating schemes, patent thickets, and long-dated contracts have also deterred the entry of approved biosimilars. “We’re not going to play regulatory whack-a-mole with companies trying to unfairly delay or derail the entry of biosimilar competitors,” said Gottlieb.
In another effort to stave off competition from biosimilars, some payers have required step therapy or prior authorization on the reference biologic before patients are able to access a biosimilar. This is a practice that, according to Gottlieb, the FDA sees “no clinical rationale for,” due to the fact that in order for a biosimilar to be approved, the developer must demonstrate that the potential biosimilar has no clinically meaningful differences to the reference product.
Gottlieb also highlighted some key actions the FDA is taking to further spur competition and bring more biosimilars to the market, such as:
Gottlieb said that the FDA looks forward to participating with the FTC to identify ways to deter anticompetitive behavior and that those efforts “will be announced soon.”
In his final remarks, Gottlieb stressed that encouraging the competition of biosimilars in the US marketplace is not a task the FDA can accomplish alone. Achieving the cost savings projected by biosimilars will require actions from both the public and private sector to align reimbursement and formularies to encourage appropriate biosimilar adoption, drawing attention to and taking action against anticompetitive practices, and educating “providers and patients about biosimilars, and why people should have confidence in the safety and effectiveness of these FDA-approved products," he said.
Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick
April 22nd 2025Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
President Trump Signs Executive Order to Bring Down Drug Prices
April 16th 2025To help bring down sky-high drug prices, President Donald Trump signed an executive order pushing for faster biosimilar development, more transparency, and tougher rules on pharmacy benefit managers—aiming to save billions and make meds more affordable for everyone.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets
April 14th 2025During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.
Experts Pressure Congress to Remove Roadblocks for Biosimilars
April 12th 2025Lawmakers and expert witnesses emphasized the potential of biosimilars to lower health care costs by overcoming barriers like pharmacy benefit manager practices, limited awareness, and regulatory delays to improve access and competition in chronic disease management during a recent congressional hearing.